文献速递心力衰竭与心肌病

达格列净在心力衰竭伴肾功能恶化患者中的应用

Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.
PubMed 文献 · J Am Coll Cardiol · 2023-08-25

基于DAPA-HF与DELIVER试验的汇总分析显示,在11,007例心衰患者中,347例(3.2%)随访期间eGFR降至<25 mL/min/1.73 m²,其心血管复合终点风险升高(HR 1.87)。达格列净在eGFR恶化与未恶化患者中均降低主要终点风险(HR分别为0.53与0.78,交互P=0.17),且治疗组间安全性事件率相似。

要点

  • eGFR降至<25 mL/min/1.73 m²的心衰患者主要复合终点风险升高(HR 1.87)。
  • 达格列净在eGFR恶化患者中主要终点风险降低(HR 0.53),与未恶化者获益一致。
  • eGFR恶化患者中治疗组间安全事件率相似,支持继续使用达格列净。

核心结论

  • 心衰患者eGFR降至<25 mL/min/1.73 m²时心血管结局风险升高,但继续达格列净治疗仍具获益且未增加安全性事件。

研究设计与样本

  • DAPA-HF与DELIVER试验的参与者水平汇总分析,共11,007例心衰患者,采用时变Cox比例风险模型评估关联。

主要发现

  • 347例(3.2%)随访期间至少一次eGFR降至<25 mL/min/1.73 m²,其首要复合结局风险更高(HR 1.87;95%CI 1.48-2.35;P<0.001)。
  • 达格列净组主要结局风险在eGFR恶化患者中HR 0.53(95%CI 0.33-0.83),未恶化患者中HR 0.78(95%CI 0.72-0.86),交互P=0.17。
  • eGFR恶化患者安全性结局(包括停药)风险较高,但治疗组间发生率相似,包括继续用药者。

临床怎么用

  • 心衰患者eGFR降至<25 mL/min/1.73 m²时,继续达格列净治疗可能获益大于风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are guideline recommended in the management of heart failure (HF). Although these therapies can be initiated even in patients with comorbid chronic kidney disease, some patients may face deterioration of kidney function over time. OBJECTIVES: In this study, the authors sought to examine the safety and efficacy of continuing SGLT2 inhibitors in HF when the estimated glomerular filtration rate (eGFR) falls below thresholds for initiation. METHODS: Associations between a deterioration of eGFR to <25 mL/min/1.73 m2, efficacy, and safety outcomes and treatment with dapagliflozin were evaluated in time-updated Cox proportional hazard models in a participant-level pooled analysis of the DAPA-HF (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trials. RESULTS: Among 11,007 patients, 347 (3.2%) experienced a deterioration of eGFR to <25 mL/min/1.73 m2 at least once in follow-up. These patients had a higher risk of the primary composite outcome (HR: 1.87; 95% CI: 1.48-2.35; P < 0.001). The risk of the primary outcome was lower with dapagliflozin compared with placebo among patients who did (HR: 0.53; 95% CI: 0.33-0.83) as well as did not (HR: 0.78; 95% CI: 0.72-0.86) experience deterioration of eGFR to <25 mL/min/1.73 m2 (Pinteraction = 0.17). The risk of safety outcomes, including drug discontinuation, was higher among patients with deterioration of eGFR to <25 mL/min/1.73 m2; however, rates remained similar between treatment groups including among those who remained on study drug. CONCLUSIONS: Patients with deterioration of eGFR to <25 mL/min/1.73 m2 had elevated risks of cardiovascular outcomes yet appeared to benefit from continuation of dapagliflozin with no excess in safety outcomes between treatment groups. The benefit-to-risk ratio may favor continuation of dapagliflozin treatment in patients with HF experiencing deterioration of kidney function. Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124; and Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Chatur, Vaduganathan, Claggett, et al. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. J Am Coll Cardiol. 2023. PMID: 37634707. doi:10.1016/j.jacc.2023.08.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。